Abstract
BackgroundClinical trials for ovarian cancer using immune checkpoint inhibitors (ICI) as monotherapy have failed to show an improvement in survival, however, improved response rates and survival have been achieved with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have